Industry Analysis & Industry Trends
With healthcare reform allowing more individuals to gain prescription coverage, brand-name pharmaceutical and medicine manufacturers will experience a boost in demand. Rising production of branded follow-on biologic drugs will be important in offsetting the effects of widespread patent expirations, though a major increase in taxes and discounts to fill the Medicare coverage gap threatens profit in the industry... purchase to read more
Industry Report - Industry Analysis Chapter
Brand-name pharmaceutical manufacturers have contended with the patent cliff, which caused many blockbuster drugs to lose their patent exclusivity from 2010 to 2012. As a result of the patent cliff, many low-cost generic versions of brand-name drugs have inundated the market, thus intensifying competition for industry operators. In response, many pharmaceutical manufacturers have consolidated to cut their operational costs and have the resources necessary to invest in research and development (R&D). For example, many manufacturers have moved toward including biological drugs in their drug pipeline.
During the five years to 2015, industry revenue is expected to grow at an annualized rate of 1.2% to $158.7 billion, with revenue growth being slowed by the patent cliff... purchase to read more